BioCentury
ARTICLE | Company News

SciClone, Soligenix deal

July 15, 2013 7:00 AM UTC

Soligenix granted SciClone Chinese marketing rights to SGX942 to treat oral mucositis (OM). In exchange, SciClone granted Soligenix access to SciClone's clinical and regulatory data library, including Phase II studies of SCV-07 to treat OM. SciClone discontinued development of SCV-07 last year after a pre-planned interim analysis of OM patients with head and neck cancer receiving concurrent chemoradiation in a Phase IIb trial showed that the compound would not meet the pre-specified efficacy endpoints vs. placebo. According to Soligenix, data from SciClone could increase the success of Phase II testing of SGX942, which is expected to begin before year end. The companies said specific terms were not disclosed (see BioCentury, March 5, 2012). ...